Chondroitin Sulfate (Herb/Suppl)

Brand and Other Names:CDS, condroitin, more...GAG, galactosaminoglucuronoglycan

Suggested Dosing

Osteoarthritis

200-400 mg PO BID-TID, OR

1000-1200 mg PO qD

Also used in combo with glucosamine

MI, recurrent prophylaxis

Initial: 10 g PO div TID x 3 months THEN

Maintenance: 500 mg PO TID

Next:

Suggested Uses

Osteoarthritis, hyperlipidemia, ischemic heart disease, osteoporosis

Efficacy

A compilation of the studies indicates patients with OA of the knee can experience some benefit from taking chondroitin; however, pain relief is likely to be modest or possibly insignificant.

MI: Some preliminary evidence indicates a possible lower risk of MI or recurrent risk of MI. More studies are needed

Previous
Next:

Adverse Effects

Allergic reactions, alopecia, constipation, diarrhea, edema, (eyelid/lower limb), epigastric pain, extrasystoles, nausea

Previous
Next:

Warnings

Contraindications

Anticoagulated (IM use), clotting disorders (IM use)

Cautions

Asthma

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: avoid use

Lactation: avoid use

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Metabolism: N/A

Excretion: N/A

Mechanism of Action

Cartilage derivative; component of hyaline cartilage matrix that may repair cartilage & reduce synovial inflammation

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.